Temporary vascular occlusion with poloxamer 407

被引:76
作者
Raymond, J
Metcalfe, A
Salazkin, I
Schwarz, A
机构
[1] Notre Dame Hosp, CHUM Res Ctr, Intervent Neuroradiol Lab, Montreal, PQ H2L 4M1, Canada
[2] Ecole Polytech, Inst Biomed Engn, Montreal, PQ H3C 3A7, Canada
[3] Biosphere Med Inc, Rockland, MA 02370 USA
基金
加拿大健康研究院;
关键词
poloxamer; endovascular; occlusion; inverse thermosensitivity; surfactant;
D O I
10.1016/j.biomaterials.2003.10.085
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
There is a need for safe and reversible occlusions during percutaneous endovascular procedures. Poloxamer 407 is a non-ionic surfactant with rapid reversible sot-gel transition behaviour. The safety and efficacy of this polymer as a temporary embolic agent was investigated. First, dissolution time after gelation of poloxamer was determined in an in vitro model. Then, transient poloxamer occlusion of renal and pulmonary arteries of seven dogs was followed by serial angiograms. Macroscopic and pathological changes were studied I week later. This experiment was repeated in similar arteries in one pig, and in auricular arteries of two rabbits. Poloxamer dissolution after in vitro polymerization was completed within 1-20 h, depending on concentrations. In vivo poloxamer 22% injections led to complete occlusion, followed by full recanalization within 10-90 min without complication. The only biochemical effect of poloxamer occlusions was transient elevation of triglyceride levels. There were no pathological abnormalities at I week. Poloxamer 407 could be used as an embolic material for temporary occlusions. (C) 2003 Elsevier Ltd. All rights reserved.
引用
收藏
页码:3983 / 3989
页数:7
相关论文
共 12 条
[1]   INHIBITION OF RED BLOOD CELL-INDUCED PLATELET-AGGREGATION IN WHOLE-BLOOD BY A NONIONIC SURFACTANT, POLOXAMER 188 (RHEOTHRX(R) INJECTION) [J].
ARMSTRONG, JK ;
MEISELMAN, HJ ;
FISHER, TC .
THROMBOSIS RESEARCH, 1995, 79 (5-6) :437-450
[2]   Dose-dependent hyperlipidemia in rabbits following administration of poloxamer 407 gel [J].
Blonder, JM ;
Baird, L ;
Fulfs, JC ;
Rosenthal, GJ .
LIFE SCIENCES, 1999, 65 (21) :PL261-PL266
[3]   Temperature-responsive gels and thermogelling polymer matrices for protein and peptide delivery [J].
Bromberg, LE ;
Ron, ES .
ADVANCED DRUG DELIVERY REVIEWS, 1998, 31 (03) :197-221
[4]   Study of the gelation process of polyethylene oxide(a) polypropylene oxide(b) polyethylene oxide(a) copolymer (Poloxamer 407) aqueous solutions [J].
Cabana, A ;
AitKadi, A ;
Juhasz, J .
JOURNAL OF COLLOID AND INTERFACE SCIENCE, 1997, 190 (02) :307-312
[5]  
CARR ME, 1991, THROMB HAEMOSTASIS, V66, P565
[6]   Effects of poloxamer 407 on the assembly, structure and dissolution of fibrin clots [J].
Carr, ME ;
Carr, SL ;
High, AA .
BLOOD COAGULATION & FIBRINOLYSIS, 1996, 7 (02) :109-113
[7]   Synthesis and characterization of self-assembling block copolymers containing bioadhesive end groups [J].
Huang, K ;
Lee, BP ;
Ingram, DR ;
Messersmith, PB .
BIOMACROMOLECULES, 2002, 3 (02) :397-406
[8]   Randomized, controlled trial of RheothRx (poloxamer 188) in patients with suspected acute myocardial infarction [J].
Maynard, C ;
Swenson, R ;
Paris, JA ;
Martin, JS ;
Hallstrom, AP ;
Cerqueira, MD ;
Weaver, WD .
AMERICAN HEART JOURNAL, 1998, 135 (05) :797-804
[9]  
Nace V.M., 1996, SURFACTANT SCI SERIE, V60
[10]   Poloxamer-188 as an adjunct to primary percutaneous transluminal coronary angioplasty for acute myocardial infarction [J].
OKeefe, JH ;
Grines, CL ;
DeWood, MA ;
Schaer, GL ;
Browne, K ;
Magorien, RD ;
Kalbfleisch, JM ;
Fletcher, WO ;
Bateman, TM ;
Gibbons, RJ .
AMERICAN JOURNAL OF CARDIOLOGY, 1996, 78 (07) :747-750